Search results
Results from the WOW.Com Content Network
Mammary-type myofibroblastoma [14] Myofibrobastoma, also termed myofibroblastoma of soft tissues, is a mammary-type myofibroblastoma that occurs in non-mammary tissues [15] and may be as much as 10-fold more common than the mammary type. [14] Calcifying aponeurotic fibroma, also termed aponeurotic fibroma [16]
Currently, however, inflammatory pseudotumor designates a large and heterogeneous group of soft tissue tumors that includes inflammatory myofibroblastic tumor, plasma cell granuloma, xanthomatous pseudotumor, solitary mast cell granuloma, inflammatory fibrosarcoma, [4] pseudosarcomatous myofibroblastic proliferation, myofibroblastoma ...
Medical imaging may suggest but cannot prove that a tumor is MFB. Mammography, computed tomography scans, and magnetic resonance imaging of mammary [1] [12] and extramammary [1] [13] MFB typically show well-defined and well-circumscribed tumors which in almost all cases have no calcifications; these results suggest that the tumor is not malignant but do not indicate which type it might be.
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
Alternate or supplemental treatments used to treat IDF include injection of the glucocorticoid, triamcinolone, or the chemotherapy drug, 5-fluorouracil, directly into the lesions. [3] Since these injection treatments have not been evaluated in large studies to date, surgical resection is the most accepted treatment of highly symptomatic or ...
Myofibroblasts usually stain for the intermediate filament vimentin, which is a general mesenchymal marker, α-smooth muscle actin (human gene = ACTA2), and for palladin, which is a cytoskeletal actin scaffold protein.
Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas. [1] As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of fibroblasts and smooth muscle cells) by Mentzel et al. in 1998. [2]
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel diseaseBiological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]